TLR3 and prostate carcinoma: Alternately, in prostate cancer, butyrate has been shown to accelerate tumor progression by inducing autophagy and upregulating the chemokine CCL20 through TLR3 signaling, ultimately recruiting M2-like macrophages that support immune suppression [47].